The disclosure provides biosynthetic platforms that generate olivetolic acid and its analogues at high titers from microbes, and in cell free systems.

Characterization of the binding dynamics at the interface between any two proteins that specifically interact plays a role in myriad biomedical applications. The methods disclosed herein provide for the high-throughput characterization of the specific interaction at the interface between two protein binding partners and the identification of functionally significant mutations of one or both protein binding partners. For example, the methods disclosed herein may be useful for epitope and paratope mapping of an antibody-antigen pair, which is useful for the discovery and development of novel therapies, vaccines, diagnostics, among other biomedical applications.

The present invention relates to isolated polypeptides having beta-glucanase activity, catalytic domains, carbohydrate binding modules and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding modules. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding modules. The present invention further relates to processes for producing fermentation products from starch-containing or cellulosic-containing material, as well as an enzyme blend or composition, or a recombinant host cell or fermenting organism suitable for use in processes of the invention.

The present disclosure provides compositions and methods for gene editing. The disclosure also provides methods for removing extra-chromosomally replicating plasmids from competent cells.

Described herein are single chain trimer (SCT) polypeptides comprising or consisting essentially of a target peptide, a first linker, at least a portion of a beta-2 microglobulin domain, a second linker, and at least a portion of a major histocompatibility complex (MHC) I alpha chain, or pharmaceutically acceptable derivatives thereof. The SCT polypeptides may further include a leader peptide, e.g., a PHO5, SUC2, app8, or HLA A2 leader sequence at the N-terminus of the target peptide. Further described herein are polypeptide compositions comprising or consisting essentially of a first polypeptide comprising a target peptide, and a second polypeptide comprising at least a portion of a beta-2 microglobulin domain, a second linker, and at least a portion of a major histocompatibility complex (MHC) I alpha chain, a third linker, and a tether peptide, or pharmaceutically acceptable derivatives thereof. The first polypeptide and/or the second polypeptide may further include a leader peptide, e.g., a PHO5, SUC2, app8, or HLA A2 leader sequence. The present disclosure also includes associated kits, methods, compositions, nucleotides, cells, and uses thereof.

Disclosed is a technique for constructing optogenetic amplifier and inverter circuits utilizing transcriptional activator/repressor pairs, in which expression of the transcriptional activator or repressor, respectively, is controlled by light-controlled transcription factors. This system is demonstrated utilizing the quinic acid regulon system from Neurospora crassa, or Q System, a transcriptional activator/repressor system. This is also demonstrated utilizing the galactose regulon from Saccharomyces cerevisiae, or GAL System. Such optogenetic amplifier circuits enable multi-phase microbial fermentations, in which different light schedules are applied in each phase to dynamically control different metabolic pathways for the production of proteins, fuels or chemicals. The orthogonal nature of the Q and GAL systems enable the co-expression of amplifier and inverter circuits to simultaneously amplify and invert the response of light-controlled transcriptional controls over different sets of genes in the same cell.

Glucuronosyltransferase 1 gene which catalyzes glucuronic acid transfer to the hydroxyl group at the 3-position in an oleanane-type triterpenoid is identified. Glucuronosyltransferase 1 gene having a desired activity, derived from a Fabaceae plant (soybean, Glycyrrhiza, and Lotus japonicus), and containing nucleotide sequences represented by SEQ ID Nos: 2, 4, and 6, respectively, is provided.

The present disclosure provides recombinant microorganisms and methods for producing malonate semialdehyde and/or related products, such as ketones, alcohols, organic acids, esters, alkenes, amino acids, and combinations thereof including 3-hydroxypropionic acid, acrylic acid, propionic acid, 1-propanol, acetone, 2-propanol, butanone, 1-butanol, 2-butanol, methyl propionate, 1,3-propanediol, isoamyl alcohol, 1,3-butanediol, 1,4-butanediol, 2,3-butanediol, lactic acid, adipic acid, glutamic acid, itaconic acid, ethyl acetate, isopropyl acetate, acetic acid, butyric acid, caproic acid, citric acid, methacrylic acid, succinic acid, propylene, butadiene, ethanol, isoprenol, leucine, isoleucine, glutamine, glycine, and isoprene, from β-alanine. The recombinant microorganism expresses an asparate 1-decarboxylase that catalyzes the production of malonate semialdehyde from β-alanine.

Provided herein, inter alia, are methods and compositions for identifying major histocompatibility class II (MEW II) complex binding peptides.

Provided are a novel promoter, a vector including the same, a microorganism including the same, and a method of producing glutathione using the same.